Constitutively Active Androgen Receptor Variants Upregulate Expression of Mesenchymal Markers in Prostate Cancer Cells

Androgen receptor (AR) signaling pathway remains the foremost target of novel therapeutics for castration-resistant prostate cancer (CRPC). However, the expression of constitutively active AR variants lacking the carboxy-terminal region in CRPC may lead to therapy inefficacy. These AR variants are s...

Descripción completa

Detalles Bibliográficos
Autores principales: Cottard, Félicie, Asmane, Irène, Erdmann, Eva, Bergerat, Jean-Pierre, Kurtz, Jean-Emmanuel, Céraline, Jocelyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3642121/
https://www.ncbi.nlm.nih.gov/pubmed/23658830
http://dx.doi.org/10.1371/journal.pone.0063466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3642121/
https://www.ncbi.nlm.nih.gov/pubmed/23658830
http://dx.doi.org/10.1371/journal.pone.0063466

Ejemplares similares